Biote Lawsuit 2026: Claims, Injuries & Settlement

Quick Answer Box

• What the case is: Litigation against Biote Medical, a Texas-based hormone pellet therapy company, alleging patients suffered serious harm including cancer, blood clots, and cardiovascular events from inadequately tested and improperly marketed subcutaneous hormone pellets.
• Who qualifies: Adults who received Biote-brand hormone pellet implants and subsequently experienced breast cancer, deep vein thrombosis, pulmonary embolism, stroke, heart attack, or other documented serious adverse events linked to hormone exposure.
• What it's worth: Individual claim values have not been set by a formal settlement fund as of early 2026; comparable hormone therapy mass tort settlements in prior litigation have ranged from $50,000 to $500,000+ depending on injury severity, documented medical costs, and causation strength.

Case Snapshot

The Biote Lawsuit: What Is Actually Being Alleged

The Biote lawsuit is personal injury litigation targeting Biote Medical LLC and affiliated entities for allegedly placing a hormone pellet therapy system into widespread commercial use without adequate safety data, proper informed consent infrastructure, or sufficient warnings about serious adverse health risks.

Biote operates a franchise-style physician certification model. The company trains and certifies thousands of physicians across the United States to implant subcutaneous testosterone and estradiol pellets under the skin. Those pellets release hormones continuously over three to six months.

Here is something related: AI Lawsuit News 2026: Cases, Claims, Who Qualifies

Plaintiffs allege Biote marketed this system aggressively to physicians and patients while downplaying or omitting known risks of hormone-sensitive cancers, thromboembolic events, and cardiovascular complications. The legal exposure for Biote is compounded by its hybrid role as both product supplier and training system operator.

*Attorney Insight: Attorneys handling these claims note that Biote's physician-certification model creates a layered liability structure because the company arguably controlled not just the product but the clinical protocols physicians followed.*

Key Allegations at a Glance:

• Failure to adequately warn patients and physicians of cancer risks
• Fraudulent misrepresentation of safety and efficacy in marketing materials
• Negligence in pellet dosing protocols and insertion training
• Breach of implied warranty of merchantability and fitness
• Off-label use promotion without supporting clinical evidence

Biote Lawsuit 2026: Where the Litigation Stands Right Now

As of early 2026, Biote-related personal injury claims are active litigation, not settled cases. The absence of a centralized MDL means the litigation landscape is fragmented across state and federal courts.

Individual lawsuits have been filed in Texas, Florida, California, and other high-population states where Biote-certified physicians operate in large numbers. Plaintiff law firms actively recruiting claimants have publicly indicated thousands of potential plaintiffs have been identified based on reported adverse event patterns.

No global settlement has been announced. Biote has not made any public admission of liability. The litigation is in early-to-mid pretrial stages, with discovery disputes and Daubert challenges on expert testimony expected to dominate 2026 proceedings.

*Attorney Insight: Attorneys experienced in pharmaceutical mass torts point out that the pretrial science battles, specifically whether plaintiffs can establish general causation through expert testimony, will largely determine whether individual trials proceed or whether global settlement becomes economically rational for the defense.*

2026 Litigation Status Milestones:

Biote Hormone Pellet Lawsuit: The Product at the Center of the Claims

The Biote hormone pellet lawsuit centers on a specific drug delivery method. Biote-branded pellets are small, rice-sized cylinders compounded from crystalline testosterone or estradiol.

A Biote-certified physician inserts these pellets subcutaneously, typically in the upper buttock. The pellets dissolve gradually, releasing hormones into the bloodstream over approximately three to six months. Unlike FDA-approved hormone therapy products, which undergo rigorous clinical trials, compounded hormone pellets occupy a regulatory gray zone.

FDA has repeatedly stated it has not approved any compounded bioidentical hormone therapy as safe and effective. Plaintiffs argue Biote exploited this regulatory gap to market an undertested product as a superior alternative to conventional hormone therapy without adequate clinical backing.

*Attorney Insight: Attorneys on these cases frequently cite the FDA's repeated public communications about compounded bioidentical hormones as key documentary evidence supporting failure-to-warn and negligence claims.*

Biote Pellet Therapy: Key Product Facts

• Composed of compounded testosterone or estradiol (not FDA-approved drug products)
• Inserted subcutaneously every 3 to 6 months
• Pellet size and dose customized by Biote-certified physician
• Cannot be removed once inserted if adverse reactions occur
• Biote provides physician training, pellet supply, and patient marketing support

What Is the Biote Lawsuit About: The Core Legal Claims Explained

At its core, the Biote lawsuit is about whether the company told patients and doctors the truth about the risks of its pellet therapy system. Plaintiffs assert Biote knew or should have known that continuous, unmodifiable hormone exposure from implanted pellets carried material risks the company failed to disclose.

The primary legal theory is failure to warn. Under products liability law, a manufacturer or distributor has a duty to provide adequate warnings about risks associated with its product. Plaintiffs argue Biote's patient-facing marketing and physician training materials systematically minimized risks of cancer, clotting events, and cardiovascular harm.

A second major claim is fraudulent misrepresentation. Plaintiffs allege Biote made affirmatively false statements about the safety and superiority of pellet therapy to drive physician adoption and patient uptake, creating a commercial ecosystem built on misleading health claims.

*Attorney Insight: Attorneys emphasize that the fraudulent misrepresentation claim, if it survives summary judgment, could support punitive damages in states that allow them for product liability fraud.*

Who Qualifies for the Biote Lawsuit in 2026

Eligibility for the Biote lawsuit depends on three primary factors: confirmed use of Biote-brand hormone pellets, documented serious adverse health outcomes, and a provable causal link between pellet therapy and those outcomes.

Not every patient who used Biote pellets and experienced any side effect has a viable claim. The litigation targets patients with serious, diagnosable injuries. Courts and plaintiff attorneys apply a gatekeeping function to ensure claims have factual and medical basis.

The strength of a claim correlates directly with the severity of the injury, the temporal proximity between pellet insertion and injury onset, and the absence of confounding health factors that might independently explain the harm.

*Attorney Insight: Attorneys screening Biote claims report that claimants with contemporaneous medical records documenting both the pellet insertion dates and subsequent adverse event diagnoses carry significantly stronger cases than those relying on memory alone.*

Eligibility Checklist for Biote Lawsuit:

• Received subcutaneous Biote hormone pellet implants (not just oral or topical hormone therapy)
• Diagnosed with one or more of the following after beginning pellet therapy:
• Breast cancer or other hormone-sensitive cancer
• Deep vein thrombosis (DVT)
• Pulmonary embolism
• Stroke or TIA (transient ischemic attack)
• Heart attack or serious cardiovascular event
• Pellet migration or abscess requiring surgical intervention
• Diagnosis occurred within a medically recognized timeframe following pellet implantation
• Have medical records documenting both pellet insertion and the adverse diagnosis

Biote Pellet Side Effects Lawsuit: What Injuries Are Being Claimed

The Biote pellet side effects lawsuit alleges a range of serious adverse events that plaintiffs say would not have occurred, or would have been disclosed and avoided, had the company been transparent about risks. These are not minor or temporary reactions.

The most serious allegations involve cancer. Prolonged estrogen and testosterone exposure, particularly at higher doses delivered continuously by implanted pellets, carries known associations with hormone-sensitive cancers, particularly breast cancer in women. Plaintiffs argue Biote's dosing protocols pushed patients into supraphysiologic hormone ranges without adequate monitoring protocols.

Cardiovascular and thromboembolic injuries represent the second major category. Elevated estrogen levels are established risk factors for deep vein thrombosis and pulmonary embolism. Elevated testosterone in women raises cardiovascular risk markers. Plaintiffs contend Biote failed to screen patients adequately for pre-existing risk factors before implantation.

*Attorney Insight: Medical causation experts in these cases are expected to rely on published epidemiological studies linking supraphysiologic hormone levels to clotting and cancer risk, distinguishing Biote's high-dose pellet system from lower-dose FDA-approved hormone therapies.*

Documented Injury Categories in Biote Claims:

Biote Lawsuit Injuries: The Medical Evidence Landscape

The medical evidence underlying Biote lawsuit injuries draws from decades of hormone therapy research, most notably the findings of the Women's Health Initiative (WHI) study. The WHI demonstrated that certain forms of hormone therapy increased risks of breast cancer, stroke, and blood clots in postmenopausal women.

Plaintiffs' experts are expected to argue that Biote's pellet system, by delivering continuous and often higher hormone concentrations than FDA-approved therapies, exposes patients to amplified versions of the same risks the WHI documented. The defense will likely contest whether WHI findings on different formulations and routes of administration apply to pellet therapy specifically.

This is where the litigation's science battle becomes pivotal. If plaintiffs establish general causation through admissible expert testimony, individual cases become far more viable. If courts exclude plaintiff experts under Daubert standards, the litigation faces a structural risk of collapse.

*Attorney Insight: Attorneys familiar with pharmaceutical mass torts consistently identify the Daubert hearing on general causation as the single most consequential procedural event in hormone therapy litigation.*

Litigation Watch: The general causation Daubert battle, the discovery scope over Biote's internal clinical data, and the physician-network liability question are the three defining legal issues that will shape the entire 2026 trajectory of this litigation.

Biote Pellet Cancer Lawsuit: The Breast Cancer Connection

The Biote pellet cancer lawsuit represents the most serious category of claims. Breast cancer diagnoses following Biote pellet therapy form the core of the highest-value individual cases in this litigation.

Women who received Biote estradiol and testosterone pellets and subsequently developed hormone-receptor-positive breast cancer argue there is a direct causal pathway. Hormone-receptor-positive breast cancers, which account for roughly 70 to 80 percent of all breast cancers, are driven by estrogen and progesterone. Prolonged supraphysiologic hormone exposure, plaintiffs contend, creates the precise biological environment that feeds these tumors.

Biote's marketing materials and physician training materials, according to plaintiff attorneys, promoted pellet therapy as a safe alternative to conventional HRT without the cancer risks, an assertion plaintiffs call both false and provably false based on the existing scientific literature.

*Attorney Insight: Attorneys handling breast cancer claims in this litigation note that medical records showing a patient's hormone receptor status in the cancer diagnosis documentation are critical to linking the cancer's biology directly to the pellet-delivered hormone exposure.*

Key Facts for Breast Cancer Claims:

• Hormone-receptor-positive breast cancer is the cancer type most directly linked to exogenous hormone exposure
• Biote pellets cannot be removed once inserted if cancer is diagnosed during an active pellet cycle
• Delay in removing the hormone source after cancer diagnosis may worsen outcomes
• Plaintiffs must establish prior cancer-free status before pellet therapy began to establish causation

Biote Blood Clot Lawsuit: DVT, Pulmonary Embolism, and Cardiovascular Claims

The Biote blood clot lawsuit addresses thromboembolic injuries that plaintiffs attribute to elevated hormone levels from pellet therapy. Deep vein thrombosis and pulmonary embolism are well-documented risks associated with estrogen exposure.

Oral estrogen therapy carries a higher clot risk than transdermal estrogen because oral estrogen undergoes first-pass liver metabolism, affecting clotting factor production. Biote pellets deliver estradiol directly into the bloodstream, bypassing liver metabolism. Plaintiffs argue this route does not eliminate clot risk, particularly when hormone levels exceed physiologic norms.

Several Biote claimants report DVT and pulmonary embolism events occurring within weeks to months of pellet insertion, with no prior clotting history. These temporal associations form the factual backbone of the thromboembolic claims, though proving legal causation requires more than timing alone.

*Attorney Insight: Attorneys note that hematology expert witnesses will play a central role in these claims, specifically in ruling out genetic clotting disorders like Factor V Leiden that defendants may use to argue patient predisposition rather than pellet causation.*

Blood Clot and Cardiovascular Claim Snapshot:

Biote Lawsuit Settlement: Is There a Settlement Fund in 2026

No Biote lawsuit settlement fund has been established as of early 2026. This is an active litigation in its pretrial phases, and global settlement negotiations have not been publicly announced by either the plaintiffs' steering committee or Biote's corporate counsel.

This does not mean settlements are impossible in 2026. In mass tort litigation, defendants sometimes resolve individual high-value cases quietly through confidential agreements while the broader litigation proceeds. Those individual resolutions are not the same as a global settlement fund.

You might also find this useful: Shein Lawsuit 2026: Claims, Status and Who Qualifies

The timeline for a global Biote settlement, if one occurs, will depend on several factors: whether an MDL is certified, how early bellwether trials perform, whether Biote's insurance coverage is sufficient to fund a large settlement, and whether Biote's corporate parent has the financial capacity to sustain prolonged litigation.

*Attorney Insight: Attorneys experienced in pharmaceutical mass tort settlements note that the earliest realistic window for global settlement discussions in a litigation of this type is typically 18 to 36 months after the first significant bellwether trial verdict.*

Settlement Timeline Expectations:

Litigation Watch: No global Biote settlement exists in early 2026; individual claims are being filed now and positions established in this pretrial period will directly affect each claimant's future settlement value.

Biote Lawsuit Settlement Amount: What Could Claimants Receive

No official Biote lawsuit settlement amount has been set. Settlement values in mass torts are determined case by case, based on injury severity, documented damages, and causation strength, not a flat per-claimant figure.

Comparable hormone therapy litigation provides a useful reference frame. In prior pharmaceutical and medical device mass torts involving hormone-sensitive cancer claims, individual settlements have ranged from $50,000 for less severe injuries to over $1 million for cases involving metastatic cancer diagnoses or fatal thromboembolic events. These figures are not guarantees and should not be treated as projections for any specific Biote claim.

Punitive damages represent an additional variable. In states that allow punitive damages in product liability fraud cases, juries have returned awards many times higher than compensatory damages alone. Whether Biote's conduct meets the legal standard for punitive exposure will depend on what internal company documents reveal about what Biote knew, and when.

*Attorney Insight: Attorneys consistently advise clients that building a complete damages package, including economic losses like medical bills and lost income alongside non-economic losses like pain and suffering, directly affects the settlement leverage in any individual claim.*

Factors That Increase Biote Claim Value:

• Breast cancer or fatal thromboembolic event diagnosis
• Documented supraphysiologic hormone levels in lab records
• Prior cancer screening showing cancer-free status before pellet therapy
• Evidence Biote's physician training downplayed specific risks
• Residency in a state with no punitive damages cap

Is the Biote Lawsuit a Class Action

The Biote lawsuit is not currently proceeding as a traditional class action. The distinction matters significantly to claimants.

A class action consolidates many plaintiffs with similar but relatively modest individual claims into one proceeding. Product liability cases involving serious physical injuries like cancer and blood clots are not well-suited to class action treatment because each plaintiff's injury, medical history, and damages are unique and require individual adjudication.

Instead, Biote litigation is structured as, or trending toward, mass tort litigation, where individual cases are filed separately but may be coordinated for pretrial purposes. Some state courts also use multicounty litigation (MCL) or coordinated proceeding structures to manage large volumes of related personal injury claims efficiently.

*Attorney Insight: Attorneys note the distinction is critical for clients because mass tort claimants retain individual case control and receive individual compensation based on their specific injury, unlike class action members who share a single recovery divided among the group.*

Class Action vs. Mass Tort: Key Differences

Biote Lawsuit MDL: Is Federal Coordination Coming

No Biote MDL (Multi-District Litigation) has been formally certified by the Judicial Panel on Multidistrict Litigation (JPML) as of early 2026. Whether an MDL petition will be filed and granted depends on whether the volume of federally filed Biote cases reaches the threshold where centralized pretrial coordination becomes necessary.

MDL designation is significant. When the JPML centralizes related federal cases before a single district judge, pretrial discovery, expert challenges, and motions practice become unified. This typically accelerates the litigation timeline and creates leverage for either global settlement or bellwether trials.

Plaintiff law firms with large inventories of Biote cases have financial and strategic incentives to seek MDL designation once sufficient federal cases exist. The JPML grants MDL status based on convenience of parties and witnesses, elimination of duplicative discovery, and promotion of just and efficient case resolution.

*Attorney Insight: Attorneys predict that if Biote-related federal filings reach several hundred cases within 2026, an MDL petition becomes highly likely, and claimants whose cases are already filed in federal court would be among the first transferred to the centralized court.*

MDL Process Overview:

• Step 1: Sufficient federal cases filed in multiple districts
• Step 2: Plaintiff or defense attorneys petition JPML
• Step 3: JPML hearing and briefing by interested parties
• Step 4: JPML issues transfer order, designating a single federal district
• Step 5: Centralized pretrial proceedings begin before the transferee judge

How to File a Biote Lawsuit in 2026

Filing a Biote lawsuit begins with retaining an attorney who handles pharmaceutical product liability or mass tort claims. Self-representation in litigation of this complexity is not realistic.

Once an attorney is retained, the intake process involves gathering medical records documenting pellet insertion procedures, hormone level lab results, and adverse event diagnoses. The attorney's medical team reviews this documentation to assess whether the case meets the causation threshold to proceed.

After review, the attorney files a complaint in the appropriate state or federal court. The complaint identifies the defendant entities, the legal claims, and the specific injuries and damages. From filing, the case enters the discovery phase, during which both sides exchange documents, conduct depositions, and retain expert witnesses.

*Attorney Insight: Attorneys advise that gathering medical records proactively before the initial consultation saves weeks of intake time and allows attorneys to evaluate the claim's strength more accurately at the outset.*

Steps to File a Biote Lawsuit:

1. Retain a plaintiff attorney with pharmaceutical product liability experience
2. Collect and organize all medical records related to pellet therapy and adverse events
3. Submit records to the attorney for medical review and causation analysis
4. Attorney files complaint in appropriate jurisdiction
5. Case enters discovery; depositions and expert witness retention proceed
6. Pretrial motions (including Daubert challenges) are litigated
7. Case resolves through settlement or proceeds to trial

Litigation Watch: Claimants who filed in state court early may have procedural advantages over later filers, particularly if state courts set aggressive discovery schedules or if state-specific MCL coordination begins before a federal MDL is established.

Biote Lawsuit Statute of Limitations: 2026 Filing Deadlines

The statute of limitations for a Biote lawsuit varies by state and determines how long an injured person has to file a claim before losing the right to sue permanently. Missing this deadline is typically fatal to any claim, regardless of injury severity.

Most states apply a personal injury statute of limitations of two to three years from the date of injury or, more commonly in product liability cases, from the date the plaintiff discovered (or reasonably should have discovered) that the injury was linked to the product. This "discovery rule" is critically important in Biote cases because many patients developed cancer or clotting events without initially connecting them to hormone pellet therapy.

Several states also have a statute of repose, an absolute outer limit on filing that runs from the date the product was implanted, regardless of when the injury was discovered. Texas, where Biote is headquartered and where many cases are likely filed, has a 15-year statute of repose for product liability claims under most circumstances, though specific facts can alter this analysis.

*Attorney Insight: Attorneys stress that the discovery rule tolling analysis requires a fact-specific legal opinion, not a general calendar calculation, and that claimants who believe they may be approaching any deadline should consult an attorney without delay.*

Statute of Limitations by Key State:

*Note: SOL rules are subject to legislative change and case-specific tolling analysis. Confirm current rules with a licensed attorney in your state.*

Biote Lawsuit Attorney: What Type of Lawyer Handles These Claims

A Biote lawsuit is handled by plaintiff attorneys who specialize in pharmaceutical product liability, medical device litigation, or mass tort personal injury claims. General practice attorneys or family law attorneys do not have the specialized expertise these cases require.

Attorneys handling Biote claims work on a contingency fee basis in virtually all cases. This means the client pays no upfront legal fees. The attorney receives a percentage of any recovery, typically 33 to 40 percent, only if the case resolves successfully. This structure aligns the attorney's financial interest directly with the client's outcome.

For a deeper understanding, check Drake UMG Lawsuit 2026: Claims, Court Status, Outcome

When evaluating a law firm, claimants should look for attorneys with verifiable experience in pharmaceutical mass tort litigation, a dedicated medical review team, and demonstrated familiarity with hormone therapy litigation specifically. Larger mass tort firms often have co-counsel arrangements with local counsel in the claimant's state to ensure jurisdictional coverage.

*Attorney Insight: Attorneys experienced in mass tort recruitment caution that some firms sign up large numbers of clients without the infrastructure to properly evaluate and pursue each case; claimants should ask specifically how many Biote cases the firm currently represents and what their review process looks like.*

What to Ask a Biote Lawsuit Attorney:

• How many Biote cases does your firm currently represent?
• Do you have a medical review team that analyzes records in-house?
• What is your contingency fee percentage?
• Will you be lead counsel, or will you refer the case to another firm?
• What is your timeline for completing my intake review?

Biote Medical Corporation Lawsuit: Understanding the Corporate Defendant

Biote Medical LLC and its parent entity Biote Holdings operate a distinctive business model that shapes the litigation's corporate defendant analysis. Biote is not a traditional pharmaceutical manufacturer. It is best characterized as a hormone pellet therapy platform company.

Biote sources compounded pellets from compounding pharmacies it works with, trains and certifies physicians in pellet insertion protocols, provides marketing and patient recruitment materials, and takes a fee structure tied to physician adoption of its system. This model means Biote has significant control over both the product and the clinical protocols used, without being the pharmacy that compounds the pellets or the physician who inserts them.

This creates a multi-defendant structure in most Biote cases. Plaintiffs may name Biote Medical, the specific compounding pharmacy that produced the pellets used, and in some cases the individual physician who performed the insertion procedure. Sorting out proportionate liability among these defendants is one of the central litigation strategy questions in every case.

*Attorney Insight: Attorneys note that Biote's substantial role in physician training and patient marketing makes it a more exposed defendant than a passive distributor, and internal training materials and marketing scripts are among the most prized documents in discovery.*

Biote Corporate Defendant Structure:

FDA Bioidentical Hormone Pellet Lawsuit: The Regulatory Backdrop

The FDA's regulatory posture on compounded bioidentical hormone therapy is a foundational element of the Biote lawsuit legal strategy. FDA has issued multiple public statements, consumer alerts, and regulatory guidance making clear that it has not approved any compounded bioidentical hormone therapy product as safe and effective.

Under the Federal Food, Drug, and Cosmetic Act, compounded drugs are generally exempt from FDA's new drug approval process when they meet specific criteria, including being prepared for an identified individual patient pursuant to a valid prescription. Biote's model, which involves large-scale physician training and systematic pellet supply for broad patient populations, raises questions about whether the compounded pellets at issue genuinely qualify for this exemption or whether they constitute unapproved new drugs.

Plaintiffs' attorneys argue the FDA's repeated warnings about compounded bioidentical hormones put Biote on notice of regulatory concerns it chose to ignore. This argument supports both the failure-to-warn theory and the negligence per se claim, which asserts that violating FDA regulatory requirements constitutes negligence as a matter of law.

*Attorney Insight: Attorneys point to FDA warning letters to specific compounding pharmacies regarding BHRT products as potentially powerful documentary evidence of industry-wide regulatory awareness that will be difficult for Biote to credibly claim it lacked.*

FDA and Regulatory Timeline for Compounded Bioidentical Hormones:

Frequently Asked Questions

What is the Biote lawsuit about?

The Biote lawsuit is personal injury litigation alleging that Biote Medical's hormone pellet therapy system caused serious injuries including cancer, blood clots, stroke, and cardiovascular events.

Plaintiffs contend Biote marketed its subcutaneous pellet therapy system without adequate warnings about these risks and with affirmatively misleading safety claims.

The litigation targets Biote Medical LLC, its corporate parent Biote Holdings, and in some cases the compounding pharmacies and physicians involved in specific patient cases.

Who qualifies to file a Biote hormone pellet lawsuit in 2026?

Adults who received Biote-brand subcutaneous hormone pellets and were subsequently diagnosed with breast cancer, DVT, pulmonary embolism, stroke, heart attack, or other serious hormone-related adverse events may qualify.

Eligibility requires documented medical records establishing both the pellet therapy history and the adverse diagnosis.

A plaintiff attorney with mass tort experience must evaluate each case individually to assess causation strength and evidentiary basis.

What injuries are linked to Biote pellet therapy lawsuits?

The primary injuries in Biote pellet lawsuits are hormone-sensitive cancers (particularly breast cancer), deep vein thrombosis, pulmonary embolism, stroke, and heart attack.

Secondary claims include pellet migration, insertion site infection or abscess, and hormone imbalance injuries from dosing errors.

The severity and documentation of the injury directly affect the potential value of the claim.

Has Biote reached a settlement, and how much could claimants receive?

No global Biote settlement fund has been established as of early 2026. The litigation is in active pretrial phases.

Comparable hormone therapy mass tort settlements in prior cases have ranged from $50,000 to over $1 million depending on injury severity and causation strength.

Individual confidential case resolutions are possible in 2026 even without a global fund.

Is the Biote lawsuit a class action or a mass tort MDL?

The Biote lawsuit is structured as mass tort personal injury litigation, not a class action. Each plaintiff pursues an individual claim based on their specific injuries and damages.

No federal MDL has been certified as of early 2026, though an MDL petition is anticipated if federal filings reach sufficient volume.

Mass tort structure means claimants receive individual compensation, not a shared class recovery.

How long do I have to file a Biote lawsuit before the deadline passes?

The statute of limitations for a Biote lawsuit varies by state, ranging from two to three years from the date of injury or date of discovery that the injury was connected to pellet therapy.

The discovery rule may extend the filing window for claimants who did not immediately connect their diagnosis to Biote pellet therapy.

Consulting an attorney promptly is the only reliable way to confirm the specific deadline applicable to your claim in your state.

Closing

The Biote lawsuit is real, active litigation with significant stakes for patients who suffered serious injuries following hormone pellet therapy. The absence of a global settlement in 2026 does not mean claims cannot be pursued. It means the litigation is in the critical early phase where the evidentiary record is being built.

For anyone who received Biote hormone pellets and experienced cancer, a blood clot, stroke, or cardiovascular event, the concrete next step is consulting a plaintiff attorney who specializes in pharmaceutical product liability or mass torts. Statute of limitations deadlines are jurisdiction-specific and unforgiving. Acting before that deadline is not optional.

Readers also liked: Baby Food Lawsuit 2026: Claims, Eligibility & Settlements